242 related articles for article (PubMed ID: 33302041)
1. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
2. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CD44 sensitizes cisplatin-resistance and affects Wnt/β-catenin signaling in HNSCC cells.
Roy S; Kar M; Roy S; Padhi S; Kumar A; Thakur S; Akhter Y; Gatto G; Banerjee B
Int J Biol Macromol; 2020 Apr; 149():501-512. PubMed ID: 31953176
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
6. Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.
Roy S; Kar M; Roy S; Saha A; Padhi S; Banerjee B
Cell Oncol (Dordr); 2018 Apr; 41(2):185-200. PubMed ID: 29243047
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
8. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
[TBL] [Abstract][Full Text] [Related]
9. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
10. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.
Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S
Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487
[TBL] [Abstract][Full Text] [Related]
12. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.
Leelahavanichkul K; Amornphimoltham P; Molinolo AA; Basile JR; Koontongkaew S; Gutkind JS
Mol Oncol; 2014 Feb; 8(1):105-18. PubMed ID: 24216180
[TBL] [Abstract][Full Text] [Related]
13. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
14. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
[No Abstract] [Full Text] [Related]
16. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
18. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.
Lin Y; Mallen-St Clair J; Wang G; Luo J; Palma-Diaz F; Lai C; Elashoff DA; Sharma S; Dubinett SM; St John M
Oral Oncol; 2016 Sep; 60():81-9. PubMed ID: 27531877
[TBL] [Abstract][Full Text] [Related]
20. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]